Eli Lilly Reports 56% Revenue Growth to $19.8 Billion in Latest Quarter

Eli Lilly and Company reported significant financial growth in its latest quarterly results, with revenue reaching $19.8 billion for the three months ended March 31, 2026, a 56% increase from $12.7 billion in the same period last year. The company's net income also saw a substantial rise, climbing to $7.4 billion, compared to $2.8 billion in the prior year, resulting in diluted earnings per share of $8.26, up from $3.06. This growth was primarily driven by increased sales volumes of key products, particularly Mounjaro and Zepbound, despite facing lower realized prices.

The financial performance reflects a notable shift from the previous fiscal period, where revenue was bolstered by a 65% increase in volume, although this was partially offset by a 13% decline in prices. The U.S. market contributed $12.1 billion to the total revenue, marking a 43% increase, while international sales surged by 81% to $7.7 billion. The company attributed the revenue growth to strong demand for its cardiometabolic health products, which accounted for 65% of total revenue.

Strategically, Eli Lilly has been active in expanding its product portfolio and capabilities. In March 2026, the company completed the acquisition of Ventyx Biosciences for approximately $1.1 billion, aimed at enhancing its offerings in inflammatory-mediated diseases. Additionally, the FDA approved orforglipron, branded as Foundayo, for obesity treatment, further diversifying its product lineup. The company is also investing in manufacturing expansions to meet anticipated demand for its products, which is expected to come online over the next few years.

Operationally, Eli Lilly's workforce remains robust, with a total employee headcount that supports its extensive research and development efforts. The company reported a significant increase in research and development expenses, which rose by 28% to $3.5 billion, reflecting its commitment to innovation. The effective tax rate for the quarter was 16.4%, down from 20.2% a year earlier, primarily due to the impact of non-deductible charges in the previous year.

Looking ahead, Eli Lilly anticipates continued growth driven by its cardiometabolic health products and ongoing investments in research and development. However, the company also faces challenges, including pricing pressures and regulatory scrutiny, particularly related to its agreements with the U.S. government on drug pricing. The company remains focused on navigating these challenges while leveraging its strong product pipeline to sustain its growth trajectory.